Sources of Extracellular, Oxidatively-Modified DNA Lesions: Implications for Their Measurement in Urine by Cooke, Marcus S. et al.
255
Serial Review J. Clin. Biochem. Nutr., 45, 255–270, November 2009
JCBN Journal of Clinical Biochemistry and Nutrition 0912-0009 1880-5086 the Society for Free Radical Research Japan Kyoto, Japan jcbnSR09-41 10.3164/jcbn.SR09-41 Serial Review Oxidative Stress-Induced Carcinogenesis and Its Prevention
Guest Editor: Shinya Toyokuni
Sources of Extracellular, Oxidatively-Modified DNA Lesions: 
Implications for Their Measurement in Urine
Marcus S. Cooke1,2,*, Paul T. Henderson3, and Mark D. Evans1
1Radiation and Oxidative Stress Section, Department of Cancer Studies and Molecular Medicine, 
Robert Kilpatrick Clinical Sciences Bilding, University of Leicester, LE2 7LX, UK
2Department of Genetics, Robert Kilpatrick Clinical Sciences Building, University of Leicester, 
Leicester, LE2 7LX, UK
3Department of Internal Medicine, University of California Davis Medical Center, Sacramento, CA, USA
11 2009 30 10 2009 45 3 255 270 Received 23.4.2009 ; accepted 29.4.2009
*To whom correspondence should be addressed.    
Tel: +44(0)116 2525825    Fax: +44 (0)116 2525832    
E-mail: msc5@le.ac.uk
Received 23 April, 2009; Accepted 29 April, 2009
Copyright © 2009 JCBN Summary There is a robust mechanistic basis for the role of oxidation damage to DNA in the
aetiology of various major diseases (cardiovascular, neurodegenerative, cancer). Robust,
validated biomarkers are needed to measure oxidative damage in the context of molecular
epidemiology, to clarify risks associated with oxidative stress, to improve our understanding
of its role in health and disease and to test intervention strategies to ameliorate it. Of the
urinary biomarkers for DNA oxidation, 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG) is the
most studied. However, there are a number of factors which hamper our complete understand-
ing of what meausrement of this lesion in urine actually represents. DNA repair is thought to
be a major contributor to urinary 8-oxodG levels, although the precise pathway(s) has not
been proven, plus possible contribution from cell turnover and diet are possible confounders.
Most recently, evidence has arisen which suggests that nucleotide salvage of 8-oxodG and
8-oxoGua can contribute substantially to 8-oxoG levels in DNA and RNA, at least in rapidly
dividing cells. This new observation may add an further confounder to the conclusion that
8-oxoGua or 8-oxodG, and its nucleobase equivalent 8-oxoguanine, concentrations in urine
are simply a consequence of DNA repair. Further studies are required to define the relative
contributions of metabolism, disease and diet to oxidised nucleic acids and their metabolites
in urine in order to develop urinalyis as a better tool for understanding human disease.
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Introduction
Normal cellular metabolism results in the continual pro-
duction of reactive oxygen species (ROS). However, expo-
sure to xenobiotics, ionising and nonionsing radiation etc.
may lead to an increased production that overwhelms the
antioxidant defences, leading to a condition of oxidative
stress. Even normal levels of ROS production leads to modi-
fication of cellular biomolecules, such as DNA, lipids and
proteins, for the most part, without detrimental effects upon
the cell. However, under oxidative stress, levels of modifica-
tion increase and this may have implications for cellular
function.M.S. Cooke et al.
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Perhaps most studied, is oxidative modification of DNA,
and whilst the principle consequence of this might be muta-
tions, it should not be forgotten that ROS-induced damage
to DNA may have non-mutational effects, such as the
acceleration of telomere shortening [1]. Over 30 nucleobase
modifications have been described, of which 8-oxo-7,8-
dihydroguanine (8-oxoGua, and its corresponding deoxyri-
bonucleoside equivalent, 8-oxo-7,8-dihydro-2'-deoxygua-
nosine, 8-oxodG; Fig. 1), have received the greatest amount
of attention [2], although the total number of DNA lesions
(including sugar and phosphate modifications, and combina-
tions thereof) is approaching 70 [3]. DNA may also be
modified via reactive intermediates, arising from the inter-
action of ROS with lipids and proteins, leading to adducts
such as 1,N6-etheno-2'-deoxyadenosine (εdA), 3-(2-deoxy-
β-D-erythro-pentofuranosyl)pyrimido[1,2-α]purin-10(3H)-
one (M1dG) and DNA-protein cross-links [4].
There is a rapidly growing body evidence which suggests
that this plethora of lesions, arising from oxidative stress,
may have an important role in the aetiology and/or patho-
genesis of many diseases, such as cancer and aging
(reviewed in Cooke et al. [5]). To fully understand the extent
to which such DNA lesions are involved in disease, in order
to develop diagnostic/prognostic methods and intervention
strategies, methods for their analysis are essential. A wide
variety of approaches have been employed to study oxida-
tively damaged DNA. However, findings from the European
Standards Committee on Oxidative DNA Damage (ESCODD
[6]), have suggested that a number of these techniques suffer
from artefactual oxidation during sample workup and
analysis (reviewed by Guetens et al. [7]). Of relevance to
all the above techniques is the possibility of adventitious
oxidation during sample storage and, with the exception of
the cell-based methods, DNA extraction, although methods
have been developed to minimise this risk [8].
Assessment of damage to DNA by methods requiring
invasive procedures, e.g. blood samples or tissue biopsy,
imposes severe limitations in large-scale human studies,
requiring staff with specialist training, greater ethical
scrutiny, and reducing the likelihood of consent. In constrast,
examining the products of oxidatively generated damage to
DNA in extracellular matrices offers a means by which
oxidative stress may be assessed non-, or minimally, inva-
sively, and circumvents DNA extraction and associated risk
of artefact.
Methods of Analysis
Broadly, methods that have been applied to the study
of oxidatively damaged DNA lesions in urine are either
chromatographic [principally, HPLC-MS/MS; liquid chro-
matography pre-purification prior to GC-MS (i.e. HPLC-
GC/MS), HPLC-EC, GC-MS], or immunoassay. Whilst a
variety of lesions have been reported to be present in urine
(Table 1), the majority of assays focus upon 8-oxodG as the
analyte of choice, in part, for reasons that will be discussed
later.
Chromatographic techniques
Whilst thymine (and thymidine) glycol was one of the
first ROS-induced DNA lesions to be studied in urine [9,
10], this was rapidly superceded by 8-oxodG, given the one
thousand-fold greater sensitivity of 8-oxodG detection using
HPLC-EC, compared to the UV detection of Tg, along with
the predominance of 8-oxodG over Tg, in human urine [11].
A number of methods based upon column-switching HPLC
with regular reverse phase (usually C18) separative columns
and EC-detection for assay of 8-oxodG have been developed
[6, 12–14]. An approach shown to be successful in a wide
variety of biological matrices (including DNA, urine, plasma,
red blood cell extracts, cerebrospinal fluid, saliva, sweat,
kidney dialysate, brain and muscle microdialysate, food
(rat, mouse, monkey and human chow), Caenorhabitbditis
elegans, cell culture medium and rat faeces), utilises an
HPLC column comprising ‘treated’ carbon material, similar
to that used for EC detector cells, together with Coularray,
multichannel electrochemical detection [15].
At its simplest, column switching has meant that, following
chromatographic separation of the urine’s constituents, only
the fraction containing the compound of interest (e.g. 8-
oxodG) is applied to the final separation column and
detector, either EC [16, 17] or MS [18]; the remainder is
diverted to waste. Benefits of mass spectrometry include: the
use of isotopically-labelled internal standards, simplifying
quantification and accounting for loss during sample workup
(and potentially storage), differences in ionisation efficiencies
due to matrix effects, and confirmation of analyte identity.
The HPLC-MS/MS assay described by Weimann et al. [18]
was the first report for the simultaneous analysis of the
oxidised (8-oxoGua, 8-oxoguanosine and 8-oxodG) and
native (Gua, guanosine and dG) moieties. Similarly, the
Fig. 1. Structures of (A) 8-oxo-7,8-dihydroguanine (8-oxoGua),
and (B) 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG).Sources of Urinary DNA Damage
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HPLC-GC/MS assay of Olinski’s laboratory entails HPLC
pre-purification of the compounds of interest, which again
includes native compounds; 8-oxoGua, 8-oxodG, Gua, dG
and 5-(hydroxymethyl)uracil (5-HMUra), [19,  20], prior
to derivatisation and GC-MS. Other urinary, oxidatively
modified DNA (2'-deoxy)nucleobase products measured in
urine include 5-hydroxyuracil (5-OHUra), 8-oxo-7,8-
dihydroadenine (8-oxoAde) [21], 5-hydroxymethyl-2'-
deoxyuridine (5-OHmUrd) [22], M1dG [23], εdA [24] and
3,N4-etheno-2'-deoxycytidine (εdC) [25].
Solid phase extraction (SPE) has been used for the
analysis of urinary 8-oxodG by GC-MS [26] and HPLC-MS/
MS, the latter of which minimised the incidence of
interfering peaks reported by Lin et al. [26] in 10–20% of
their urine samples [27]. The analysis of urinary 8-oxodA
has been attempted previously [28], but levels were reported
to be at, or below, the limit of detection for the HPLC-MS/
MS assay (0.3 nM, 7.5 fmol injected, S/N = 3). A similar
finding was noted with an SPE-based HPLC-MS/MS assay
[29].
Whilst not as prevalent as methods for analysing primary
DNA products of oxidation in urine, the analysis of
secondary DNA products of oxidation reactions in urine is
a rapidly growing area of interest. Several methods have
been developed for the measurement of lipid peroxidation-
induced etheno-DNA adducts in human urine. For example,
HPLC-fluorescence detection of εdA [30]; isotope dilution-
gas chromatography-negative ion chemical ionization/mass
spectrometry methodology for 3,N4-ethenocytosine (εCyt)
and 3,N4-ethenodeoxycytidine (εdC) [31, 32]; HPLC MS/
MS analysis of urinary εdA [24] and εdC [33] and a 32P-
postlabeling method has been reported for εdC in human
urine [25].
Although not presently used for urinary analysis of DNA
oxidation products, accelerator mass spectrometry (AMS) is
an emerging technology for measuring radiocarbon-labeled
nucleotides and nucleosides [34–38]. For radiocarbon, AMS
has attomole sensitivity for DNA samples as small as a
microgram. This technology is currently used with HPLC
to measure pharmacokinetics and metabolism of xenobiotics
[39–42] and, more recently, 8-oxodG metabolism [36].
Immunoassay
Competitive enzyme-linked immunosorbent assay
(ELISA) has received widespread, and growing, use for the
analysis of lesions in extracellular matrices. Predominantly,
8-oxodG has been the lesion of choice for commercially
available (e.g. from the Japanese Institute for the Control of
Aging, JaICA), and custom made [43] ELISAs. The benefits
of ELISA are (i) ease of use; (ii) no specialist (or indeed
expensive) equipment is required; (iii) potential application
to numerous extracellular matrices (serum [44], plasma [45],
saliva [46, 47], urine [48], CSF [49, 50], cell culture medium
[51–53] and sputum [54]; (iv) other than centrifugation of
cloudy specimens, no pre-treatment of urine is required (v)
high throughput. The kit from JaICA has, by far, received
the most published use.
Table 1. DNA-derived markers of oxidative stress examined1) in human urine.
1) Examined, but not necessarily detected.
Nucleobase Modification Abbreviation
Gua 8-oxo-7,8-dihydroguanine 8-oxoGua
8-oxo-7,8-dihydro-2'-deoxyguanosine 8-oxodG
8-oxo-7,8-dihydroguanosine 8-oxoG
Pyrimido[1,2-a]purin-10(3H)-one M1Gua
3-(2-deoxy-β-D-erythro-pentofuranosyl)pyrimido[1,2-α]purin-10(3H)-one M1dG
1, N2-ethenoguanine 1, N2-εGua
N2-3-ethenoguanine N2-3-εGua
Ade 8-oxo-7,8-dihydroadenine 8-oxoAde
8-oxo-7,8-dihydro-2'-deoxyadenosine 8-oxodA
1,N6-etheno-2'-deoxyadenosine εdA
Thy Thymine glycol Tg
Thymidine glycol dTg
5-(hydroxymethyl)uracil 5-HMUra
5-hydroxymethyl-2'-deoxyuridine 5-HMdUrd
5-hydroxyuracil 5-OHUra
Cyt 3,N4-ethenocytosine εCyt
3,N4-etheno-2'-deoxycytidine εdCM.S. Cooke et al.
J. Clin. Biochem. Nutr.
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Sources of Extracellular, Oxidatively-Modified DNA
Lesions
The possible sources of extracellular, oxidatively-
modified, DNA lesions are: (i) DNA repair, (ii) diet, (iii)
cell death/turnover, mitochondrial turnover and, most re-
cently added to this list, (iv) cellular uptake and re-utilisation
of damage products.
DNA repair
The DNA N-glycosylases responsible for removing
modified bases are increasingly well defined [2, 55]. The
prevailing thought is that quantitatively, BER is by far the
most important route for the removal of the majority of
oxidatively-derived lesions. At its simplest, this process
involves a specific enzyme, with a defined repertoire of
substrate, removing the modified base, leaving an apurinic-
apyrimidinic (AP) site. The subsequent fate of this AP site is
proposed to be dependent upon whether the glycosylase
also possesses an AP lyase activity, and may involve simply
the removal of one nucleotide (short patch repair), or 2–6
nucleotides (long patch repair), followed by gap filling and
ligation [56].
The glycosylase considered to have the primary activity in
removing 8-oxoGua in human cells, is the human 8-oxoGua
glycosylase 1 (hOGG1 [57, 58]). This enzyme acts via short
patch repair, and has a specificity for 8-oxoGua:Cyt pairs
present in double-stranded DNA, i.e. formed in situ (Fig. 2).
The activity of hOGG1 is complemented by another enzyme,
denoted hOGG2, which appears to have similarities to
prokaryotic endonuclease VII (Nei) enzymes. It has been
reported that hOGG2, removes the 8-oxoGua from the
nascent strand in 8-oxoGua:Ade or 8-oxoGua:Gua pairs,
arising from misincorporation of 8-OH-dGTP (REF 50).
Subsequent studies of eukaryotic NEI-like glycosylases
(NEIL) suggest that while these enzymes, NEIL1 and NEIL2,
can act on single stranded DNA and thus may have functions
in DNA replication/transcription, OGG2 is possibly distinct
from NEIL1 and NEIL2 on the basis of size and/or substrate
specificity. However, it still would appaear that neither
the protein nor the gene for OGG2 has been squenced, or
formally identified as an existing, characterised, enzyme.
Certainly 8-oxoGua appears to be a substrate for glycosy-
lases other than OGG1 (NEIL1, NEIL2, NTH1) in various
contexts, for example in single-stranded DNA, proximal to a
3'-end, or mispaired with Gua [59, 60] (Fig. 2).
The contribution of OGG1 enzyme to levels of urinary
8-oxoGua has been examined in OGG1 −/− mice, which
Fig. 2. DNA repair sources of extracellular 8-oxodG and 8-oxoGua. NER, nucleotide excision repair; hOGG1 and hOGG2, human
8-oxoguanine glycosylase (1 and 2); NIR, nucleotide incision repair; MMR, mis-match repair.Sources of Urinary DNA Damage
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showed a 26% reduction in the deficient strain, compared
to wild type, indicating that, in mice at least, OGG1 is a
significant, but by no means unique, source of urinary 8-
oxoGua [61]. The results clearly support the existence of
back up DNA glycosylase(s), such as the Nei-like glycosy-
lases [62], but which cannot entirely compensate for OGG1
deficiency.
In contrast, the presence of 2'-deoxyribonucleoside lesions
in extracellular matrices is less well-defined, not least as
there are no reports of a single DNA repair enzyme whose
activity yields 8-oxodG. Based upon existing evidence, we
suggest the following DNA repair routes (Fig. 2) as likely
contributors to the presence of oxidatively-modified 2'-
deoxyribonucleosides in urine:
Nudix hydrolases. Free deoxynucleotides have a greater
propensity for oxidation compared to base-paired deoxy-
nucleotides in DNA [63]. Furthermore, mitochondrial
sources of dNTPs are larger than nuclear sources (mitochon-
dria: 18.0 pmol dGTP/μg DNA versus nuclear: 8.0 pmol
dGTP/μg DNA [64]). Taken together, these would suggest
an imperative for preventing modified DNA precursors
being incorporated into the genome. The best characterised
enzyme which performs such a role is the 8-oxo-2'-
deoxyguanosine triphosphatase (8-oxodGTPase [65]) activity
of NUDT1 (aka MutT homologue, MTH1), hydrolysing 8-
oxodGTP to 8-oxodGMP (Fig. 2). It has been suggested that
further processing, perhaps by 5'(3')-nucleotidases, may give
rise to 8-oxodG [65], which can be removed from the cell to
ultimately appear in the urine. Recent data from the group of
Harms-Ringdahl strongly imply that NUDT1 activity, and
thus the nucleotide pool, represents a major source of extra-
cellular 8-oxodG [66]. However, the roles of other Nudix
hydrolases such as NUDT15 (MTH2) and NUDT5, which
include 8-oxodGTP and 8-oxodGDP amongst their substrate
repertoire respectively, remain to be defined [67, 68].
Nucleotide excision repair (NER). Principally, NER re-
moves bulky lesions, such as cyclobutane thymine dimers
(T<>T), although there is there is some evidence for activity
towards 8-oxodG (Fig. 2) [69]. Indeed, the rate of 8-oxoGua
removal appears comparable to that for T<>T [69], the
implication being that a lesion-containing oligomer, approx-
imately 24–32 nucleotides long is then produced [70].
Galloway  et al. [ 71] showed that, post-excision, T<>T-
containing oligomers are subsequently degraded to lesion-
containing 7-mers. What then happens to the oligomers is
unknown, although, from the findings of Le Curieux and
Hemminki [72], who detected the presence of urinary T<>T
as a monophosphate nucleotide dimer, it may be implied that
further processing does occur, the nature of which remains to
be described. The situation for 8-oxodG is even less clear as
a recent report failed to demonstrate 8-oxoGua-containing
oligomers in urine [73] implying that further processing
occurs, perhaps ultimately yielding 8-oxodG, or that they
do not exist. However, under normal circumstances, when
BER and NER are allowed to compete, NER appears to
have a negligible role in the removal of 8-oxoGua [74–78].
Eliminating Ogg1 activity (Ogg1−/− mice) while reducing 8-
oxoGua excretion by 26%, has no impact on the excretion of
8-oxodG compared to wild-type animals [61]. This perhaps
suggests that other BER activities compensate for lost
OGG1 activity, or if NER is contributing, it is either minimal
even under these circumstances or 8-oxoGua-containing
oligomers are not subject to further degradation. Results
from experiments with XP cell lines have not entirely
excluded the possibility of a role for NER in the repair of
8-oxoGua, however some XP proteins are also thought to
play a role in BER, through modulating OGG1 activity,
for example [69, 75, 79–81].
Nucleotide Incision Repair (NIR). This is a more recently
described DNA repair pathway whose lesion repertoire is
more oriented towards oxidised pyrimidines, rather than
purines. However, dependent on the structural context, 8-
oxoGua can be a substrate, when 8-oxo-Gua is present at
the 3'-end of a DNA strand break, such a situation could
occur from mis-incorporation of 8-oxodGMP during DNA
synthesis or damage induced by ionising radiation, in this
context 8-oxoGua is reistant to excision by OGG1. The 3'-5'
exonuclease activity of Apn1, in S. cerevisiae, and APE-1,
in humans, has been demostrated to fulfill this NIR activity
towards 8-oxoGua in such a context [82, 83]. An important
issue with this pathway is that the initial product of NIR is a
lesion-containing 2'-deoxyribonucleoside 3'-monophosphate,
which could then be a substrate for a 5'(3')-nucleotidase
activity, to yield 8-oxodG.
Mismatch Repair (MMR). The recognition of mis-incor-
porated 8-oxoGua either opposite G or A can render the le-
sion a substrate for MMR [84, 85]. Recognition of the mis-
pair by  MutSα and MutLα heterodimeric complexes ulti-
mately invokes a long-patch repair process in which exonu-
clease I, targeted to the nascent strand, sequentially removes
2'-deoxynucleotide monophosphates in the 5'-3' direction,
again gnerating a lesion-containing that could be further
degraded 8-oxodG by a 5'(3')-nucleotidase activity.
Endonuclease(s). A poorly characterised endonuclease
has been reported by Bessho et al. [86] which, lacking a
glycosylase activity, is predicted to give rise to 3',5'-8-
oxodGDP as the putative product. We have previously pro-
posed that this may be subsequently hydrolysed to 8-oxodG
by nucleotidase(s).
As noted earlier, in addition to 8-oxodG, the following
modified 2'-deoxyribonucleosides have been identified inM.S. Cooke et al.
J. Clin. Biochem. Nutr.
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urine: dTg, 5-OHmUrd, M1dG,  εdA, and εdC, and their
origins are even less clear.
Potential confounders
Diet. The majority of reports measuring oxidatively
modified DNA lesions in urine, have focussed upon 2'-
deoxyribonucleoside lesions, and 8-oxodG specifically. The
reason for this is because early work in the field demon-
strated that diet could affect levels of urinary 8-oxoGua,
but not 8-oxodG. Whilst it was concluded that Tg was
unaffected by diet, the raw data would suggest otherwise:
gastric intubation of rats demonstrated that 44% of ingested
[3H]-Tg was recovered intact in the urine within 24 h ([87]
and discussed in detail by Cooke et al. [88]). It is worth
noting that the results from the HPLC-based assay used in
the Park et al. [89] paper, examining urinary 8-oxoGua and
8-oxodG are perhaps questionable, as the assay utilised a
monoclonal antibody which was not entirely specific for 8-
oxodG. There would appear to be little human data on the
subject of dietary contribution, not all of which agree with
the animal findings. Gackowski et al. [90] have suggested
that, in humans, neither 8-oxoGua, nor 8-oxodG, are affected
by diet. However, pivotal to this study was the assumption
that, like rats [89], humans reach a minimum level of 8-
oxoGua excretion 2–3 days after switching to a nucleic acid-
free diet. Similarly, it was assumed that a maximum level of
8-oxoGua excretion was reached 3–5 days after reverting to
a normal diet. Additional sampling points throughout this
study would make these conclusions more definitive.
In contrast, there is agreement between all studies showing
that urinary 2'-deoxynucleoside lesions, are unaffected by
diet. In rats, this was demonstrated by both the nucleic acid-
free diet studies and intubation studies (only 1% of [3H]-8-
oxodG and 5% of [3H]- thymidine glycol, dTg, appeared in
the urine; [91] and [87], respectively). Cathcart et al. [87]
suggest that the low levels of radioactivity probably derive
from faecal contamination of the urine samples, the true
values being closer to zero. In humans, the results of
Gackowski [90], described above, concur with the studies
in rats.
For completeness, it is worth considering ribonucleoside
lesions, although there have been very few reports examining
oxidatively-modified ribonucleosides in urine [18,  92].
Such studies may be justified by reports which suggest a
negligible contribution from diet to urinary modified
ribonucleoside levels [93,  94]. However, there are also
data that indicate diet influences urinary levels of 8-oxoGuo,
in rats at least (nucleic acid-free diet excreted 908 +/−
357 pmol of 8-oxoG/kg/day, compared to 2810 +/−
830 pmol of 8-oxodGuo/kg/day for those fed normal chow
[89].
Urinary levels of another lesion, N2-methyl-8-oxo-7,8-
dihydroguanine, have been measured and noted to be elevated
in ill and growing infants, initially suggesting a role for
this oxidatively-modified tRNA component as a marker of
oxidative stress [95]. However, its apparent absence in
tRNA and reduction in urinary levels following administra-
tion of allopurinol, would suggest its production and
appearance in urine is due to the action of xanthine dehydro-
genase/oxidase, clearly ruling out its use as a biomarker of
tRNA oxidation [95]. In contrast, 8-oxoGuo and 8-oxodG
excretion was unaffected by administration of allopurinol
[95], as was 8-oxoGua excretion (Helbock et al. unpublished
results, refered to in [95]), further supporting the compounds
are biomarkers of oxidatively generated damage.
Whilst oxidative modification of DNA bases, such as 8-
oxoGua, may have a number of detrimental consequences
for the cell [1], including mutation [2], the significance of
oxidatively modified ribonucleosides is not so well defined
[1], but may be associated with abnormal protein translation
and defects in protein synthesis [96–98]. It is concluded
that the source, and certainly the significance, of oxidatively
modified ribonucleosides in urine is even less clear than
for nucleobases and 2'-deoxyribonucleosides, particularly as
some oxidised ribonucleosides may be products of cellular
synthesis and may be considered endogenous. Further studies,
preferably in humans, examining the source and significance
of extracellular, oxidatively-modified ribonucleosides are
clearly warranted. This is all the more important in the light
of recent work describing the role of Y-box binding protein
1 and polynucleotide phosphorylase [99] in sequestering
8-oxoGua-containing transcripts (the possibility of RNA
‘repair’ is considered in greater detail in Evans and Cooke
[1]) coupled with the observations that oxidised mRNA
induces trnaslational errors [100].
Recent human studies investigating dietary contribution
Upon ingestion, nucleic acids are rapidly fragmented, by
mastication combined with enzymic digestion and acid
hydrolysis in the buccal cavity and gastro-intestinal tract
(GIT [101]). Enzymes which can catalyse hydrolysis include
DNase I, from salivary glands, the pancreas, liver and
Paneth cells of the small intestine, may be present in high
concentrations, combined with DNase II, whose optimal pH
(4.6–5.5) makes it particularly suited to activity in the upper
GIT [101]. The low pH of the stomach may allow depurina-
tion of DNA, generating free adenine and guanine, as in vitro
studies have shown [102], although it is not clear whether
this is the case for 8-oxodG, as the N-glycosidic bond
appears to be very chemically stable [103].
Even though specific transport systems are reported to
exist for bases and nucleosides, for healthy, well-nourished
individuals, reliance on dietary sources of nucleosides to
supplement salvage and de novo synthesis is negligible
[104]. Furthermore, even in those tissues that do apparentlySources of Urinary DNA Damage
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utilise dietary sources of nucleosides to supplement endo-
genous nucleotide synthesis, e.g. bone marrow and intestine,
the contribution from diet is still regarded as minimal.
Enterocytes may absorb some dietary nucleosides, but in the
case of dietary purine nucleosides significant catabolism in
the proximal small intestine results in complete degradation
of these species to uric acid [105, 106], this is in contrast to
pyrimidines which do show some incorporation in cellular
nucleic acids [107]. Collectively, it would appear unlikely
that diet contributes to the levels of oxidatively-modified
purines in urine, although the case for pyrimidine lesions
may not be quite as clear. Nevertheless, a definitive exclu-
sion of dietary contribution, is still required, and may have
to be explored on a lesion-by-lesion basis.
Studies utilising radio-labelled lesions are preferred over
those involving nucleic acid-free diets as the use of radio-
labels provides a degree of stringency not afforded by
nucleic acid-free diets (possible short-comings of nucleic
acid-free diets have been discussed above). For example,
the presence of labelled lesions in the urine/faeces, cross-
contamination notwithstanding, can only come from the
dietary source. However, for ethical reasons, radio-labelled
lesions are to be avoided in human studies. To circumvent
this issue, Cooke et al. [20] reported a feeding study using
heavily damaged, stable isotopically-labelled [15N]-DNA
(98% incorporation) and discussed thoroughly the fate of
ingested DNA. The [15N]-DNA, had been irradiated with a
dose of 50 kJ/m2 UVC shown, by a previous study, to induce
approximately 600 8-oxodG/105 dG [108].
Healthy, male volunteers were fed 5, 15 or 25 mg of
the damaged [15N]-DNA, and first void, mid-stream urine
samples were collected for up to 14 days later. The presence
of [15N5]-8-oxodG, and [15N5]-8-oxoGua in urine was
investigated using HPLC-GC/MS [90]. Neither lesion was
detected in any of the urine samples. To confirm that the
absence of lesion was not a sensitivity issue, urinary [15N5]-
dG and [15N5]-Gua, which should be present at significant
levels, was also examined. Again, neither of these labelled
compounds were detected in any of the urine samples. The
authors also investigated whether any of the ingested [15N5]-
Gua/dG had been degraded to [15N5]-uric acid, the final
product of purine metabolism, prior to excretion, again, no
labelled material was detected.
Unlike previous studies, which had only been performed
in animals, the authors also examined the DNA from peri-
pheral blood mononuclear cells (PBMC), collected for up
to seven days following ingestion of labelled DNA, for
possible incorporation of label. The justification for this
derived from reports that phage DNA may appear in a
diverse range of cell types, including PBMC, 24 h after
ingestion by mice [109, 110], implying that a proportion of
DNA consumed is not entirely degraded, and may be both
absorbed and integrated. The relevance of such findings to
plant and animal DNA has been questioned [101]. Yet again,
no [15N5]-labelled Gua, or [15N5]-8-oxoGua, was detected in
the PBMC DNA. This result is consistent with previous
findings, in mice and chickens, that dietary purines, are not
incorporated into cellular nucleic acids [107]. No informa-
tion on pyrimidine components was presented.
As with previous studies [111], Cooke et al. [20] could
only presume that the isotopically labelled DNA compo-
nents/adducts pass through the gastro-intestinal tract to
appear in faeces. Nevertheless, these results, coupled with
the findings of Gackowski et al. [ 90], provide the most
compelling argument that diet is not a significant contributor
to both urinary 8-oxoGua and 8-oxodG levels in human
urine. This is consistent with the animal data relating to 2'-
deoxyribonucleoside lesions [111], which includes dTg [87],
but disagrees with early data for 8-oxoGua and Tg [87, 112].
Species differences may be proposed to account for this
discrepancy, although the focus of our attention must be
upon the more relevant, human data. Earlier animal studies
should be repeated using the highly specific and sensitive
mass spectrometric techniques.
Cell death/turnover. It has been stated that urinary 8-
oxodG does not reflect DNA repair, as it is not a product
of base excision repair [113], rather it was a product of
non-specific nucleases, acting upon DNA released during
cell death, liberating dG which is subsequently oxidised
(or indeed free 8-oxodG itself). Such a hypothesis did not
leave scope for the potential existence of other, as yet
undiscovered, repair pathways, which may yield 8-oxodG,
and in any case, oxidation of dG in the systemic circulations
does not appear to occur (discussed below, under Issues of
artefact and stability). Whilst repair processes, whose
reaction product may be 8-oxodG, have subsequently been
described (see above), the possible contribution from cell
turnover remains to be addressed. Indeed, most of the
evidence against a contribution from cell turnover is
anecdotal. For example, there exists a number of reports in
which urinary 8-oxodG has been measured in patients
undergoing chemotherapy, in which cytotoxic agents are
used to cause (cancer) cell death. No increases in urinary
8-oxodG were noted in the studies of both Faure et al. [114]
and Erhola et al. [115], despite evidence of extensive cell
death i.e. significant increases (p<0.01) in urinary uric acid
(a biochemical index of cell turnover); and reduction in
tumour mass. Furthermore any reported increases in urinary
8-oxodG following chemo- or radiotherapy have been
attributed entirely to DNA repair [116, 117]. Thus far, the
most decisive argument against the contribution of cell
death to urinary levels of 8-oxodG and 8-oxoGua comes
from a report from the Olinski group [118]. This study
revealed that a statistically significant (p = 0.0003) increase
(60%) in 8-oxoGua was observed 24 h after infusion of theM.S. Cooke et al.
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cisplatin, a period when no loss of blood cells was reported.
In the “nadir days”, when the most distinct cell death can be
observed, urinary excretion of 8-oxoGua dropped signifi-
cantly in comparison with the aforementioned time point.
The implication being that cell death does not appear to
contribute to urinary 8-oxoGua (and 8-oxodG) in humans.
Is there any evidence to suggest that 8-oxodG may be
liberated from DNA whilst in the systemic circulation?
Perhaps. It has been reported that rat liver homogenates
can release 8-oxodG from oxidatively-modified DNA [119].
The authors suggest that, during DNA degradation, most of
the 8-oxodG, present in DNA, is released by enzymes, and
subsequently appears in the urine, implying this to be a
major source. However, they do acknowledge their system
does not accurately represent the in vivo situation, not least
as it is unrealistic—multiple, uncompartmentalised nucleases
acting upon circulating DNA, particularly as the majority of
cell death in healthy humans will be via apoptosis.
It has been suggested by Cooke et al. [120] that were cell
death to be the primary source of urinary lesions, the ratio
between native and modified, in urine, would be similar to
that seen in cells (reportedly anywhere between one 8-
oxodG/105 and one 8-oxodG/107 dG [121], although the
recommendation from ESCODD is that the level in lympho-
cytes is likely to be somewhere between 4.2 and 0.3 8-
oxodG per 106 dG [8]. In fact the ratio appears to be very
close. For the 2'-deoxyribonucleoside: 28 (+/− 2) 8-oxodG:
12 (+/− 2) dG nmol/24 h, although not as close for the
nucleobase: 136 +/− 12 8-oxoGua: 1931 (+/− 182) Gua
nmol/24 h [18]. Neither ratio even approaches that seen in
cells. Of course, were dG or Gua to be metabolised upon
release from DNA, as reported by Shi et al. [119], this could
account for the closeness of the ratio. Indeed this suggestion
might be supported by the findings of Bialkowski et al.
[103], who noted that the N-glycosidic bond is more stable
for 8-oxodG, than dG. Nevertheless, Weimann et al. [73], in
a study examining oligonucleotides in urine, concluded that
the limited excretion of oligonucleotides into urine argues
against oligonucleotides, or indeed nucleosides, originating
from cell death [73]. On balance, these results suggest that
the contribution of cell death to urinary 8-oxodG levels is
minimal, but clearly further work needs to be performed.
Uptake and re-utilisation. In contrast to 8-oxoG in DNA,
little information is available on the mutagenic potential
and cellular responses to the presence of free 8-oxodG. The
cellular metabolism of 8-oxodG is the subject of an
emerging and sometimes conflicting literature. In human
cells, dG predominantly undergoes phosphorolysis by
purine nucleoside phosphorylase (PNP) to form the free
nucleobase Gua and 2'-deoxyribose-1'-phosphate. The
resulting free nucleobase is a substrate for hypoxanthine-
guanine phosphoribosyltransferase (HGPRT), resulting in
formation of GMP. Two additional phosphorylation steps
afford GTP, which serves as a substrate for RNA poly-
merase-dependent incorporation into RNA. This pathway
can also feed into DNA synthesis, since GDP can be reduced
to dGDP by ribonucleotide reductase (RR) by replacement
of the 2'-OH with a hydrogen atom. This pathway is repre-
sented schematically by:
dG→Gua→GMP→GDP→GTP→RNA
and
dG→Gua→GMP→GDP→dGDP→dGTP→DNA
Alternatively, cellular deoxycytidine kinase (dCK) or mi-
tochondrial deoxyguanosine kinase (dGK) phosphorylate
dG to form dGMP, which can then be serially phosphory-
lated to dGTP prior to incorporation into DNA during
replication or repair synthesis:
dG→dGMP→dGDP→dGTP→DNA.
Based upon the known nucleotide salvage pathways for
dG, 8-oxodG may also be metabolized by two distinct path-
ways.
(1) If 8-oxodG is a substrate for PNP, the nucleobase
portion of 8-oxodG can be hydrolyzed from the 2'-deoxyri-
bose ring. The resulting 8-oxoGua is a substrate for
nucleotide salvage, resulting in the ribonucleotide and
2'-deoxyribonucleotide triphosphates 8-oxoGTP and 8-
oxodGTP, respectively, which contribute to RNA and DNA
synthesis.
(2) Direct mono-, di- and triphosphorylation of 8-oxodG
would result in formation of 8-oxodGTP, a substrate for
DNA synthesis [122–128]. Both possible pathways reflect
the known metabolism of the canonical 2'-deoxynucleoside
dG described above [129–131]. However, nucleotide
salavage of 8-oxodG is complicated by contributions from
BER via OGG1 and OGG2 and nucleotide pool “cleansing”
by nudix hydrolases and 5'-nucleotidase activity as shown
in Fig. 3.
In an effort to determine whether 8-oxodG is a substrate
for the human nucleotide salvage pathways that utilize dG,
Henderson and coworkers measured [14C]8-oxodG metabo-
lism in MCF-7 cells [35]. The [14C]8-oxodG was labeled on
the nucleobase in order to probe both possible nucleotide
salvage mechanisms. AMS was required for the study since
the levels of 14C-labeled metabolites were too low be be
detected by other mass spectrometry methods and well
below the limit of detection for liquid scintillation counting.
The ability of cells dosed with extracellular 8-oxodG to
import 8-oxodG and employ either PNP-dependent nucle-
otide salvage or direct phosphorylation for nucleic acidSources of Urinary DNA Damage
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synthesis was investigated. Incorporation of exogoenous 8-
oxodG was observed at a concentration of approximately
one 8-oxoG nucleobase per 107 nucleotides in DNA and
one 8-oxoG per 106 nucleotides in RNA, in cells exposed to
concentrations of 8-oxodG approximating those present in
human plasma (~100 fmol per mL) [89]. Resulting levels
of 8-oxoGua incorporated into DNA and RNA, were at
concentrations within an order of magnitude of those typi-
cally reported for mammalian cells as measured by HPLC-
EC [8].
These initial observations were accompanied by inhibitor-
based experiments aimed at determining the mechanism of
incorporation. The [14C]8-oxodG experiments were repeated
in the presence of inhibitors of PNP, RR and dCK [132]. The
inhibition of PNP almost completely abrogated incorpora-
tion of radiocarbon into both DNA and RNA, indicating
PNP as a gatekeeper of 8-oxodG catabolism. Inhibition of
RR resulted in reduced radiocarbon incorporation into DNA,
but had little effect on 8-oxoG incorporation into RNA,
indicating that 8-oxoGDP is a substrate for RR, which leads
to incorporation of the nucleobase portion of the exogenous
8-oxodG into DNA. Inhibition of dCK had no effect on
radiocarbon incorporation into DNA and RNA compared to
controls with no inhibitor, supporting, at best, a minimal
contribution by direct phosphorylation of 8-oxodG to the
overall metabolism, which is in contrast to catabolism of dG
[132].
An intruiging possible consequence of nucleotide salvage
for DNA and nucleotide pool repair pathways is the produc-
tion of both 8-oxodG and 8-oxoGua that may ultimately be
excreted in urine. Prevention of the incorporation of 8-
oxodG into DNA or RNA derives from the activity of MTH1
and 5'-nucleotidase. Whether 8-oxodGMP is a substrate for
cellular dGMP nucleotidase activity remains unanswered.
The recently published data on exogenous 8-oxodG is in
partial agreement with the literature. For example, Zeng
et al. [ 133] demonstrated that HGPRT can catalyse the
formation of 8-oxoGuo monophosphate from 8-oxoGua,
Fig. 3. Potential fate of extracellular 8-oxodG, and 8-oxoGua, by metabolic salvage pathways. Neither 8-oxodG, nor 8-oxodGMP can
be phosphorylated, as they are not substrates for deoxynucleoside kinase, or guanylate kinase, respectively. Therefore the
alternative pathway, discussed by Hah et al. [35], relies upon degradation of extracellular 8-oxodG to 8-oxoGua, perhaps by
purine nucleoside phosphorylase (PNP). 6-Hydroxypurine phosphoribosyltransferase (HGPRTase) can catalyse the formation
of 8-oxoguanosine monophosphate, providing a route for the oxidised moiety, via nucleoside-phosphate kinase (NPK) and
nucleoside-diphosphate kinase (NDK), to be incorporated into RNA. In this model ribonucleoside-diphosphate reductase
(RDR) is responsible for the conversion of 8-oxoguanine-containing ribonucleotides to deoxyribonucleotide equivalents.
Nucleoside-diphosphate kinase then catalyses the phosphorylation of 8-oxodGDP to 8-oxo-7,8-dihydro-2'-deoxyguanosine
triphosphate, a substrate for DNA polymerases for incorporation into DNA. Potential sources of extracellular 8-oxodG and
8-oxoGua are indicated (diet, death, DNA repair) contributions from which may have profound implications for the cell, and
our understanding of what measurement of these biomarkers of oxidative stress really means.M.S. Cooke et al.
J. Clin. Biochem. Nutr.
264
which is consistent with PNP-dependent nucleotide salvage
of 8-oxodG. However, this process has not been specifically
demonstrated to occur in vivo, even in a cell culture system.
The extracellular addition of 400 μM 8-oxodG to a number
of leukaemic cell lines (KG-1, H9, CEM-CM3, Molt-4), in
which hOGG1 activity is absent or low, results in cyto-
toxicity and the accumulation of 8-oxoGua in their nuclear
DNA [134, 135], consistent with PNP-mediated cleavage of
the glycosidic bond of 8-oxodG. However, this increase 8-
oxoGua does not appear to be due to the direct incorporation
of the extracellular 8-oxodG [136]. However, this study
reported the use of tritium-labeled 8-oxodG in which the
radioactive label resided on the 2'-deoxyribose ring, which
would be precluded from incorporation into DNA unless
there was direct phosphorylation by dCK or dGK. It has
previously been reported that 8-oxodG is not a substrate
for deoxynucleoside kinase [137] or guanylate kinase [65],
which are not required by the PNP-mediated pathway for
incorporation of 8-oxoGua into DNA or RNA. The report
by Kim et al claimed that the 8-oxodG was not substantially
degraded to 8-oxoGua, supporting the notion that the fate of
8-oxodG, once present following repair, is excreted, intact,
into extracellular compartments [136]. However, we would
have to question the biological relevence of using an extra-
cellular concentration of 400 μM 8-oxodG. For example,
Henderson and coworkers demonstrated that increasing
concentrations of 8-oxodG in the cell culture medium above
approximately 2 μM resulted in saturation of nucleotide sal-
vage resulting little or no additional incorporation into DNA
with increased 8-oxodG concentrations in the media [35].
Kim et al. [136] provided evidence concurring with an
earlier report [65] that 8-oxodG is not phosphorylated to
8-oxodGMP. The authors hypothesise that the cytotoxicity
of 8-oxodG is, in part at least, via error-prone DNA
synthesis, mediated by DNA polymerase β [136], implying
that cytosolic 8-oxodG, whilst not a substrate for (re-)
incorporation into DNA, may not be as benign as previously
thought. Alternative explanation is that very high concentra-
tions, 8-oxodG interferes with feedback inhibited control of
dGTP concentrations via PNP-mediated proceses, resulting
in toxic levels of dGTP in the cells dosed with 400 μM
8-oxodG.
Issues of artefact and stability
The potential exists, as for DNA, that urinary lesions
may arise from the artefactual oxidation of nucleobases, or
2'-deoxyribonucleosides, following exposure to metabolic
enzymes, or other oxidising species, after release into the
systemic circulation, or in the urine. However, Shigenaga
et al. [111] showed that dG is not artefactually oxidised in
the systemic circulation, or following incubation with
microsomal enzymes. Equally, 8-oxodG, Tg and dTg are
not subject to degradation upon release into the systemic
circulation ([87, 111], the stability of 8-oxoGua not having
been examined. Experimental studies with 8-oxodG injected
intravenously have shown that recovery is almost complete
in urine in pigs, implying that further metabolism in the
systemic circulation is an unlikely event [138].
Furthermore, as significant concentrations of hydrogen
peroxide have been reported to be present in urine [26, 139].
Lin et al. (2004) examined the potential for 8-oxodG to be
generated from dG, present in the urine. In a recent study
combinations of dG (1 nmol) and hydrogen peroxide (50 or
100 μM), were incubated in a number of urine samples,
for 24 h, at room temperature [26]. The authors concluded
that hydrogen peroxide has a negligible effect upon 8-oxodG
production, under these circumstances, agreeing with
previous results from Ames’ laboratory. Storage of urine
samples at –20°C does not lead to a decrease in urinary 8-
oxodG concentrations, when analysed over a 15 year period
[140], making urine an ideal matrix to store in biobanks
for future analysis.
Whilst the above provide evidence of stability in extra-
cellular matrices, it is worth noting that 8-oxodG is more
prone to oxidation than dG, due to its lower redox potential
[141,  142] and is preferentially oxidised, even in the
presence of an excess of Gua [143, 144]. By the same token,
oxidation of Thy to Tg is less likely to occur, than Gua to
8-oxoGua, due to the lower oxidation potential of Gua,
compared to Thy. However, it would appear that most of
these studies have examined the oxidation of 8-oxoGua in
situ in DNA [145], rather than as a post-excision product
of DNA repair, which may alter the likelihood of oxidation
and its ‘oxidisability’. In contrast, M1G and M1dG both
appear to undergo further oxidative metabolism in rat liver
cytosol, with the nucleobase adduct being a better substrate
for such enzymic oxidation than the deoxyribonucleoside
adduct [146, 147]. There is also some evidence to suggest
that M1G is further oxidised when administered intra-
venously, although M1dG was not examined [146].
Overall, it would appear that 8-oxodG, Tg and dTg, and
probably 8-oxoGua, are not formed artefactually in vivo, in
biological matrices of mammals, including humans, and
there is no published evidence for their degradation upon
release. In contrast, there is strong evidence that M1G and
M1dG may undergo oxidation, either enzymically, or in the
systemic circulation.
Conclusions
There is a great deal of evidence, albeit largely
circumstantial, implicating a role for oxidatively damaged
DNA in various diseases, in particular cancer [5]. Of the
biomarkers of oxidatively damaged DNA, urinary 8-oxodG
has received perhaps the most interest. The benefits of using
urine as a matrix in which to study oxidatively-modifiedSources of Urinary DNA Damage
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DNA include:
1.  Non-invasive, with ramifications for gaining ethical
approval and access to vulnerable groups.
2.  Samples are easily collected (low biological hazard,
no pre-processing prior to storage, small volumes),
stored (stable at –80°C for >10 y, with no ‘special’
treatments or preservatives) and transported.
3.  Stability of 8-oxodG in urine allows access to samples
from previous studies/biobanks.
4.  Applicable to the study of large sample size, as many
of the assays are semi-automated and with potentially
high throughput.
Measurement of this biomarker is also the closest to
validation, which includes understanding the provenence of
8-oxodG in urine, evaluation of confounding factors and
work towards inter-laboratory consensus. However, an
important caveat with validation of urinary biomarkers, is
to not simply apply the findings for one lesion, to all the
others. For example, we have noted herein that the literature
indicates that diet may contribute to levels of urinary 8-
oxoGua, but not urinary Tg. To some extent, therefore, all
lesions need to be indipendetly validated, drawing on the
experience of 8-oxo(d)G.
To accelerate this process, the European Standards
Committee of Urinary (DNA) Lesion Analysis (ESCULA)
has been formed, which now represents an international
group of >25 laboratories dedicated to the validation of
urinary biomarkers of DNA damage (further information,
including how to apply for membership, can be found at
http://escula.org ).
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